The Motley Fool Podcasts Industry Focus Healthcare: Is Zolgensma's $2.1 Million Price Tag Ridiculous?

Healthcare: Is Zolgensma's $2.1 Million Price Tag Ridiculous? Logo

Healthcare: Is Zolgensma's $2.1 Million Price Tag Ridiculous?

Here's why paying $2 million for Novartis' revolutionary gene therapy for SMA may not be as crazy as it sounds. 
Also, why shares slumped after BioMarin reported its gene therapy may virtually eliminate bleeding in hemophilia A patients.

Check out more of our content here:

Listen to Healthcare: Is Zolgensma's $2.1 Million Price Tag Ridiculous?

Recent Episodes

Listen
Listen
Listen
Listen
Listen
Listen
Listen
Listen
Listen
Listen

More Podcasts